Quantitative Assessment of Hypertrophic Obstructive Cardiomyopathy With Intraoperative Three-dimensional Transesophageal Echocardiography Under Provocative Dobutamine Stress Test
Hypertrophic Obstructive Cardiomyopathy
About this trial
This is an interventional diagnostic trial for Hypertrophic Obstructive Cardiomyopathy focused on measuring Transesophageal Echocardiography, Dobutamine Stress test
Eligibility Criteria
Inclusion Criteria:
- HOCM refractory to medical treatment with symptoms like syncope, angina or NYHA functional classes III and IV, with a resting gradient or provocable gradient equal or greater than 50 mmHg, requiring surgical intervention.
- Absence of other cardiac or systemic diseases capable of producing hypertrophy.
- Sinus rhythm.
Exclusion Criteria:
- Patient refusal.
- Patient unable to give consent.
- TEE contraindication.
- Different rhythm than sinus.
- Other systemic diseases capable of producing hypertrophy.
- Severe Aortic or coronary artery pathology.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Preoperative Transesophageal Echocardiogram (TEE) PG under anesthesia <50mmHg (Group A)
Preoperative PG under anesthesia ≥ 50mmHg (Group B)
Pre-cardiopulmonary bypass (CPB) (pre-myectomy) echocardiographic parameters: PG under DBT stress test at 5, 10, 15 and 20 mcg/kg/min or until a PG ≥ 50mmHg is achieved, will be recorded. Post-CPB (post-myectomy) echocardiographic parameters: PG at DBT peak dose (DBT-pd) will be recorded. If LVOT PG post myectomy are >16 mmHg, the surgeon will be advised, for surgical management considerations.
Pre-cardiopulmonary bypass (CPB) (pre-myectomy) echocardiographic parameters: PG without DBT stress test will be recorded. Post-CPB (post-myectomy) echocardiographic parameters: PG at 5, 10, 15, 20 mcg/kg/min DBT stress test or until the postoperative provocable PG is >16 mmHg will be recorded.